JP2005505256A5 - - Google Patents

Download PDF

Info

Publication number
JP2005505256A5
JP2005505256A5 JP2003502040A JP2003502040A JP2005505256A5 JP 2005505256 A5 JP2005505256 A5 JP 2005505256A5 JP 2003502040 A JP2003502040 A JP 2003502040A JP 2003502040 A JP2003502040 A JP 2003502040A JP 2005505256 A5 JP2005505256 A5 JP 2005505256A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
antigen
binding fragment
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003502040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505256A (ja
JP4527394B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/017402 external-priority patent/WO2002098920A1/en
Publication of JP2005505256A publication Critical patent/JP2005505256A/ja
Publication of JP2005505256A5 publication Critical patent/JP2005505256A5/ja
Application granted granted Critical
Publication of JP4527394B2 publication Critical patent/JP4527394B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003502040A 2001-06-01 2002-05-31 Kim−1の分断を阻害するための分子および方法 Expired - Fee Related JP4527394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29544901P 2001-06-01 2001-06-01
US29590701P 2001-06-04 2001-06-04
PCT/US2002/017402 WO2002098920A1 (en) 2001-06-01 2002-05-31 Molecules and methods for inhibiting shedding of kim-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010068988A Division JP2010150291A (ja) 2001-06-01 2010-03-24 Kim−1の分断を阻害するための分子および方法

Publications (3)

Publication Number Publication Date
JP2005505256A JP2005505256A (ja) 2005-02-24
JP2005505256A5 true JP2005505256A5 (enExample) 2006-01-05
JP4527394B2 JP4527394B2 (ja) 2010-08-18

Family

ID=26969139

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003502040A Expired - Fee Related JP4527394B2 (ja) 2001-06-01 2002-05-31 Kim−1の分断を阻害するための分子および方法
JP2010068988A Withdrawn JP2010150291A (ja) 2001-06-01 2010-03-24 Kim−1の分断を阻害するための分子および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010068988A Withdrawn JP2010150291A (ja) 2001-06-01 2010-03-24 Kim−1の分断を阻害するための分子および方法

Country Status (10)

Country Link
US (3) US7041290B2 (enExample)
EP (1) EP1401869B1 (enExample)
JP (2) JP4527394B2 (enExample)
AT (1) ATE382060T1 (enExample)
AU (1) AU2002305785B2 (enExample)
CA (1) CA2448427C (enExample)
DE (1) DE60224275T2 (enExample)
DK (1) DK1401869T3 (enExample)
NZ (1) NZ530457A (enExample)
WO (1) WO2002098920A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258793T5 (es) * 1996-05-24 2010-01-25 Biogen Idec Ma Inc. Moduladores de la regeneracion tisular.
ATE425249T1 (de) * 2000-06-16 2009-03-15 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
AU2003228336B2 (en) * 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2013205381B2 (en) * 2002-03-19 2016-04-14 Celldex Therapeutics, Inc. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP2025345A1 (en) * 2002-12-30 2009-02-18 Biogen Idec MA Inc. KIM-1 antagonists and use to modulate immune system
WO2004084823A2 (en) * 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
AU2013242840B2 (en) * 2003-03-19 2017-01-19 Amgen Fremont Inc. Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof
EP1532984A1 (en) * 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
KR101213894B1 (ko) * 2005-03-02 2012-12-20 바이오겐 아이덱 엠에이 인코포레이티드 Th2 매개성 병태를 치료하기 위한 kim-1 항체
EP1957115B8 (en) 2005-11-10 2014-03-05 Celldex Therapeutics, Inc. Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP2517020B1 (en) 2009-12-23 2015-10-21 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a canine
SG182408A1 (en) 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
MX340696B (es) 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
WO2013078089A1 (en) * 2011-11-22 2013-05-30 Biogen Idec Ma Inc. Anti-tim-1 antibodies and uses thereof
WO2015023836A1 (en) * 2013-08-16 2015-02-19 The Brigham And Women's Hospital, Inc. Kim-1 as a therapeutic target in conditions associated with kidney fibrosis
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
EP3568416A4 (en) * 2017-01-13 2020-07-08 Celdara Medical, LLC TIM-1 TARGETED CHIMERIC ANTIGENIC RECEPTORS
CN110799492B (zh) 2017-04-28 2023-06-27 爱康泰生治疗公司 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
PT3908568T (pt) 2019-01-11 2024-09-30 Acuitas Therapeutics Inc Lípidos para a administração de agentes ativos por nanopartículas lipídicas
ES3054438T3 (en) 2020-07-16 2026-02-03 Acuitas Therapeutics Inc Cationic lipids for use in lipid nanoparticles
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622861A (en) 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
ES2258793T5 (es) 1996-05-24 2010-01-25 Biogen Idec Ma Inc. Moduladores de la regeneracion tisular.
ATE425249T1 (de) * 2000-06-16 2009-03-15 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
US7553939B2 (en) 2001-06-29 2009-06-30 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes and methods of use thereof
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
US7470428B2 (en) 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
AU2003228336B2 (en) 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
WO2004084823A2 (en) 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
US20050119210A1 (en) 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers

Similar Documents

Publication Publication Date Title
JP2005505256A5 (enExample)
JP2005520566A5 (enExample)
JP2022120070A (ja) 抗cd71抗体、活性化可能抗cd71抗体、およびその使用方法
JP2010535713A5 (enExample)
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
JP2004534020A5 (enExample)
JP2023081303A5 (enExample)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2008529497A5 (enExample)
JP2025183307A5 (enExample)
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
JP2010513303A5 (enExample)
CA2595610A1 (en) Antibodies directed to angiopoietin-2 and uses thereof
HK1221153A1 (zh) 抗体-药物缀合物
JP2012532851A5 (enExample)
RU2013125306A (ru) Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование
JP2009197002A5 (enExample)
RU2010141584A (ru) Антитело против csf-1r
JP2010533498A5 (enExample)
JP2004518624A5 (enExample)
JP2010508847A5 (enExample)
JP2014502955A5 (enExample)
JP2008529494A5 (enExample)
CA2928895A1 (en) Antibodies against ccr9 and applications thereof
JP2025524306A (ja) Itga2を標的とする抗体及びそれを含む抗体薬物複合体